Clinical evaluation of dispersion MRI for prostate cancer localization: a multicenter study

S. Turco, Cristina Lavini, Stijn Heijmink, Jelle Barentsz, H. Wijkstra, M. Mischi

Research output: Contribution to conferencePosterAcademic

Abstract

Multiparametric magnetic resonance imaging (mpMRI) has emerged as a promising tool for prostate cancer (PCa) localization. Due to the complex acquisition procedure and analysis, along with a questioned diagnostic contribution, the inclusion of DCE-MRI in the updated Prostate Imaging and Reporting Data System (PI-RADS2) has been limited to qualitative assessment only, with a marginal weight on the final score. However, lower diagnostic performance has been reported for PI-RADS2 compared to original PI-RADS, evidencing the need to reconsider the role of DCE-MRI. Recently, magnetic resonance dispersion imaging (MRDI) has shown promise for quantitative DCE-MRI of the prostate. In MRDI, the adopted pharmacokinetic (PK) model includes description of the contrast agent intravascular transport, enabling additional assessment of the microvascular architecture. Compared to standard PK analysis in MRI, separate estimation of an arterial input function is no longer necessary, facilitating the clinical routine. Here we evaluate the diagnostic performance of MRDI for PCa localization compared to standard PK analysis by the Tofts model (TM) in a retrospective study including 80 patients from three different Dutch institutions.

Conference

Conference11th ISMRM Benelux Chapter meeting
CountryNetherlands
CityLeiden
Period17/01/1917/01/19
Internet address

Fingerprint

Multicenter Studies
Prostatic Neoplasms
Magnetic Resonance Imaging
Pharmacokinetics
Prostate
Information Systems
Contrast Media
Retrospective Studies
Weights and Measures

Keywords

  • DCE-MRI
  • Oncology
  • prostate cancer
  • pharmacokinetic modeling
  • multiparametric MRI

Cite this

Turco, S., Lavini, C., Heijmink, S., Barentsz, J., Wijkstra, H., & Mischi, M. (2019). Clinical evaluation of dispersion MRI for prostate cancer localization: a multicenter study. Poster session presented at 11th ISMRM Benelux Chapter meeting, Leiden, Netherlands.
Turco, S. ; Lavini, Cristina ; Heijmink, Stijn ; Barentsz, Jelle ; Wijkstra, H. ; Mischi, M./ Clinical evaluation of dispersion MRI for prostate cancer localization: a multicenter study. Poster session presented at 11th ISMRM Benelux Chapter meeting, Leiden, Netherlands.1 p.
@conference{a4acc92212d842789c678f5682bf461c,
title = "Clinical evaluation of dispersion MRI for prostate cancer localization: a multicenter study",
abstract = "Multiparametric magnetic resonance imaging (mpMRI) has emerged as a promising tool for prostate cancer (PCa) localization. Due to the complex acquisition procedure and analysis, along with a questioned diagnostic contribution, the inclusion of DCE-MRI in the updated Prostate Imaging and Reporting Data System (PI-RADS2) has been limited to qualitative assessment only, with a marginal weight on the final score. However, lower diagnostic performance has been reported for PI-RADS2 compared to original PI-RADS, evidencing the need to reconsider the role of DCE-MRI. Recently, magnetic resonance dispersion imaging (MRDI) has shown promise for quantitative DCE-MRI of the prostate. In MRDI, the adopted pharmacokinetic (PK) model includes description of the contrast agent intravascular transport, enabling additional assessment of the microvascular architecture. Compared to standard PK analysis in MRI, separate estimation of an arterial input function is no longer necessary, facilitating the clinical routine. Here we evaluate the diagnostic performance of MRDI for PCa localization compared to standard PK analysis by the Tofts model (TM) in a retrospective study including 80 patients from three different Dutch institutions.",
keywords = "DCE-MRI, Oncology, prostate cancer, pharmacokinetic modeling, multiparametric MRI",
author = "S. Turco and Cristina Lavini and Stijn Heijmink and Jelle Barentsz and H. Wijkstra and M. Mischi",
year = "2019",
language = "English",
note = "11th ISMRM Benelux Chapter meeting ; Conference date: 17-01-2019 Through 17-01-2019",
url = "http://www.ismrm-benelux.org/annual-meetings/meeting-2019/",

}

Turco, S, Lavini, C, Heijmink, S, Barentsz, J, Wijkstra, H & Mischi, M 2019, 'Clinical evaluation of dispersion MRI for prostate cancer localization: a multicenter study' 11th ISMRM Benelux Chapter meeting, Leiden, Netherlands, 17/01/19 - 17/01/19, .

Clinical evaluation of dispersion MRI for prostate cancer localization: a multicenter study. / Turco, S.; Lavini, Cristina; Heijmink, Stijn; Barentsz, Jelle; Wijkstra, H.; Mischi, M.

2019. Poster session presented at 11th ISMRM Benelux Chapter meeting, Leiden, Netherlands.

Research output: Contribution to conferencePosterAcademic

TY - CONF

T1 - Clinical evaluation of dispersion MRI for prostate cancer localization: a multicenter study

AU - Turco,S.

AU - Lavini,Cristina

AU - Heijmink,Stijn

AU - Barentsz,Jelle

AU - Wijkstra,H.

AU - Mischi,M.

PY - 2019

Y1 - 2019

N2 - Multiparametric magnetic resonance imaging (mpMRI) has emerged as a promising tool for prostate cancer (PCa) localization. Due to the complex acquisition procedure and analysis, along with a questioned diagnostic contribution, the inclusion of DCE-MRI in the updated Prostate Imaging and Reporting Data System (PI-RADS2) has been limited to qualitative assessment only, with a marginal weight on the final score. However, lower diagnostic performance has been reported for PI-RADS2 compared to original PI-RADS, evidencing the need to reconsider the role of DCE-MRI. Recently, magnetic resonance dispersion imaging (MRDI) has shown promise for quantitative DCE-MRI of the prostate. In MRDI, the adopted pharmacokinetic (PK) model includes description of the contrast agent intravascular transport, enabling additional assessment of the microvascular architecture. Compared to standard PK analysis in MRI, separate estimation of an arterial input function is no longer necessary, facilitating the clinical routine. Here we evaluate the diagnostic performance of MRDI for PCa localization compared to standard PK analysis by the Tofts model (TM) in a retrospective study including 80 patients from three different Dutch institutions.

AB - Multiparametric magnetic resonance imaging (mpMRI) has emerged as a promising tool for prostate cancer (PCa) localization. Due to the complex acquisition procedure and analysis, along with a questioned diagnostic contribution, the inclusion of DCE-MRI in the updated Prostate Imaging and Reporting Data System (PI-RADS2) has been limited to qualitative assessment only, with a marginal weight on the final score. However, lower diagnostic performance has been reported for PI-RADS2 compared to original PI-RADS, evidencing the need to reconsider the role of DCE-MRI. Recently, magnetic resonance dispersion imaging (MRDI) has shown promise for quantitative DCE-MRI of the prostate. In MRDI, the adopted pharmacokinetic (PK) model includes description of the contrast agent intravascular transport, enabling additional assessment of the microvascular architecture. Compared to standard PK analysis in MRI, separate estimation of an arterial input function is no longer necessary, facilitating the clinical routine. Here we evaluate the diagnostic performance of MRDI for PCa localization compared to standard PK analysis by the Tofts model (TM) in a retrospective study including 80 patients from three different Dutch institutions.

KW - DCE-MRI

KW - Oncology

KW - prostate cancer

KW - pharmacokinetic modeling

KW - multiparametric MRI

M3 - Poster

ER -

Turco S, Lavini C, Heijmink S, Barentsz J, Wijkstra H, Mischi M. Clinical evaluation of dispersion MRI for prostate cancer localization: a multicenter study. 2019. Poster session presented at 11th ISMRM Benelux Chapter meeting, Leiden, Netherlands.